Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Market Report: Shire chief executive vows to continue pursuing Baxalta

Jamie Nimmo
Saturday 24 October 2015 00:45 BST
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

Flemming Ornskov, the chief executive of Shire, is not a man who gives up easily. The Irish drug maker’s boss vowed to continue pursuing Baxalta despite the US rare disease firm’s apparent lack of interest in talks.

Mr Ornskov claimed he would not give up easily. He also insisted Baxalta was not the only option, but stopped short of admitting interest in Radius Health, which the FTSE 100 company has been linked with.

The comments – as well as a better-than-expected 11 per cent rise in third-quarter earnings – helped Shire jump 196p to 4,641p. Since its $30bn failed bid at the start of August, just four weeks after Baxalta was spun out of parent Baxter International, Shire’s share price has fallen more than 20 per cent.

Shire’s all-stock offer in August was worth $45 a share to Baxalta shareholders at the time. Now, it is worth just over $36 per share, making it even less attractive.

Hopes of continued economic stimulus from the ECB and a cut in China’s interest rates lifted the FTSE 100 by 67.8 points to 6,444.08, its highest point in two months.

Tech shares were among the winners after strong third-quarter earnings from Google, Amazon and Microsoft, with iPhone chipmaker Arm Holdings a beneficiary, 36p higher at 1,073p.

Publisher-turned-education provider Pearson ended a dreadful week at the bottom of the blue-chip ladder, down another 49.5p to 900.5p. Its profit warning wiped almost £2bn off its market cap this week – double what it bagged from the sale of the FT.

Investors jumped on board roadside recovery group AA as Berenberg’s bullish 350p target price drove the shares 14.1p higher to 276.6p.

On AIM, Hutchison China MediTech jumped 175p or 7 per cent to 2,612.5p as it revealed a $10m payment is due from US drug maker Eli Lilly after a joint treatment passed a Phase 2 study.

Shares in Greek mobile business software firm Globo, which have halved since June, were suspended after a short-selling attack from America’s Quintessential Capital Management.

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in